Advanced prescription of injectable anticancer drugs: Safety assessment in a European Comprehensive Cancer Centre using the risk matrix approach.
advanced prescription
anticancer drugs
medication errors
patient safety
risk management
risk matrix approach
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
25 Feb 2024
25 Feb 2024
Historique:
revised:
28
01
2024
received:
25
02
2023
accepted:
29
01
2024
medline:
26
2
2024
pubmed:
26
2
2024
entrez:
25
2
2024
Statut:
aheadofprint
Résumé
The purpose of this work was to assess failures in the advanced prescription of parenteral anticancer agents in an adult day oncology care unit with more than 100 patients per day. An a priori descriptive analysis was carried out by using the risk matrix approach. After defining the scope in a multidisciplinary meeting, we determined at each step the failure modes (FMs), their effects (E) and their associated causes (C). A severity score (S) was assigned to all effects and a probability of occurrence (O) to all causes. These S and O indicators, were used to obtain a criticality index (CI) matrix. We assessed the risk control (RC) of each failure in order to define a residual criticality index (rCI) matrix. During risk analysis, 14 FMs were detected, and 61 scenarios were identified considering all possible effects and causes. Nine situations (15%) were highlighted with the maximum CI, 18 (30%) with a medium CI, and 34 (55%) with a negligible CI. Nevertheless, among all these critical situations, only three (5%) had an rCI to process (i.e., missed dose adjustment, multiple prescriptions and abnormal biology data); the others required monitoring only. Clinicians' and pharmacists' knowledge of these critical situations enables them to manage the associated risks. Advanced prescription of injectable anticancer drugs appears to be a safe practice for patients when combined with risk management. The major risks identified concerned missed dose adjustment, prescription duplication and lack of consideration for abnormal biology data.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 British Pharmacological Society.
Références
Bonnabry P, Cingria L, Ackermann M, Sadeghipour F, Bigler L, Mach N. Use of a prospective risk analysis method to improve the safety of the cancer chemotherapy process. Int J Qual Health Care. 2006;18(1):9-16. doi:10.1093/intqhc/mzi082
Weingart SN, Zhang L, Sweeney M, Hassett M. Chemotherapy medication errors. Lancet Oncol. 2018;19(4):e191-e199. doi:10.1016/S1470-2045(18)30094-9
Velo GP, Minuz P. Medication errors: prescribing faults and prescription errors. Br J Clin Pharmacol. 2009;67(6):624-628. doi:10.1111/j.1365-2125.2009.03425.x
Bourika K, Koutras A, Kalofonos H, et al. Improvement of chemotherapy solutions production procedure in a hospital central chemotherapy preparation unit: a systematic risk assessment to prevent avoidable harm in cancer patients. Clin Med Insights Oncol. 2019;13:1179554919852933. doi:10.1177/1179554919852933
Voeffray M, Pannatier A, Stupp R, Fucina N, Leyvraz S, Wasserfallen JB. Effect of computerisation on the quality and safety of chemotherapy prescription. Qual Saf Health Care. 2006;15(6):418-421. doi:10.1136/qshc.2005.016808
Gilbert RE, Kozak MC, Dobish RB, et al. Intravenous chemotherapy compounding errors in a follow-up pan-Canadian observational study. J Oncol Pract. 2018;14(5):e295-e303. doi:10.1200/JOP.17.00007
Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995;274(1):29-34. doi:10.1001/jama.1995.03530010043033
Lesar TS, Briceland L, Stein DS. Factors related to errors in medication prescribing. JAMA. 1997;277(4):312-317. doi:10.1001/jama.1997.03540280050033
Saad A, Der-Nigoghossian CA, Njeim R, Sakr R, Salameh P, Massoud M. Prescription errors with chemotherapy: quality improvement through standardized order templates. Asian Pac J Cancer Prev. 2016;17(4):2329-2336. doi:10.7314/apjcp.2016.17.4.2329
Agulnik A, Antillon-Klussmann F, Soberanis Vasquez DJ, et al. Cost-benefit analysis of implementing a pediatric early warning system at a pediatric oncology hospital in a low-middle income country. Cancer. 2019;125(22):4052-4058. doi:10.1002/cncr.32436
Rahimi R, Moghaddasi H, Rafsanjani KA, Bahoush G, Kazemi A. Effects of chemotherapy prescription clinical decision-support systems on the chemotherapy process: a systematic review. Int J Med Inform. 2019;122:20-26. doi:10.1016/j.ijmedinf.2018.11.004
Bonnabry P, Despont-Gros C, Grauser D, et al. A risk analysis method to evaluate the impact of a computerized provider order entry system on patient safety. J Am Med Inform Assoc. 2008;15(4):453-460. doi:10.1197/jamia.M2677
Vosters O, Jaadar Y, Vidts LA, et al. Implementation of a new health information technology for the management of cancer chemotherapies. Eur J Hosp Pharm. 2018;25(5):281-285. doi:10.1136/ejhpharm-2016-001135
Bates DW, Cohen M, Leape LL, Overhage JM, Shabot MM, Sheridan T. Reducing the frequency of errors in medicine using information technology. J Am Med Inform Assoc. 2001;8(4):299-308. doi:10.1136/jamia.2001.0080299
Aita M, Belvedere O, de Carlo E, et al. Chemotherapy prescribing errors: an observational study on the role of information technology and computerized physician order entry systems. BMC Health Serv Res. 2013;13(1):522. doi:10.1186/1472-6963-13-522
Meisenberg BR, Wright RR, Brady-Copertino CJ. Reduction in chemotherapy order errors with computerized physician order entry. J Oncol Pract. 2014;10(1):e5-e9. doi:10.1200/JOP.2013.000903
Dupre M, Escalup L, Blondeel-Gomes S, et al. Errors in prescribing injectable anticancer drugs: benefits of a pharmaceutical long-term monitoring to improve patient safety in a European comprehensive cancer centre. Eur J Hosp Pharm. doi:10.1136/ejhpharm-2023-003680
Díaz-Carrasco MS, Pareja A, Yachachi A, Cortés F, Espuny A. Prescription errors in chemotherapy. Farm Hosp. 2007;31(3):161-164. doi:10.1016/s1130-6343(07)75364-3
Han JM, Ah YM, Suh SY, et al. Clinical and economic impact of pharmacists' intervention in a large volume chemotherapy preparation unit. Int J Clin Pharmacol. 2016;38(5):1124-1132. doi:10.1007/s11096-016-0339-9
Buurma H, De Smet PAGM, Leufkens HGM, Egberts ACG. Evaluation of the clinical value of pharmacists' modifications of prescription errors. Br J Clin Pharmacol. 2004;58(5):503-511. doi:10.1111/j.1365-2125.2004.02181.x
Goldspiel B, Hoffman JM, Griffith NL, et al. ASHP guidelines on preventing medication errors with chemotherapy and biotherapy. Am J Health Syst Pharm. 2015;72(8):e6-e35. doi:10.2146/sp150001
Montesi G, Lechi A. Prevention of medication errors: detection and audit. Br J Clin Pharmacol. 2009;67(6):651-655. doi:10.1111/j.1365-2125.2009.03422.x
Bonan B, Martelli N, Berhoune M, Vidal LA, Sahin E, Prognon P. FabAct®: a decision-making tool for the anticipation of the preparation of anticancer drugs. J Eval Clin Pract. 2010;16(6):1129-1135. doi:10.1111/j.1365-2753.2009.01281.x
Peyrilles E, Lepage-Seydoux C, Sejean K, Bonan B. Implementation of a remote oncology-monitoring program for cancer patients in outpatient care unit: a major challenge for the different actors. Bull Cancer. 2018;105(4):357-367. doi:10.1016/j.bulcan.2018.01.010
dos Santos M, Lequesne J, Dugué AE, et al. Optimisation of chemotherapy prescription and preparation in an ambulatory unit: validation of the OPTIMA program. Eur J Cancer Care. 2019;28(3):e13015. doi:10.1111/ecc.13015
Desmaris RP, Bermudez E, Annereau M, Lemare F, Slimano F. Organization of chemotherapeutic preparations in advance: do we save or waste money? J Oncol Pharm Pract. 2021;27(7):1699-1703. doi:10.1177/1078155220967981
Jensen RC, Bird RL, Nichols BW. Risk assessment matrices for workplace hazards: design for usability. Int J Environ Res Public Health. 2022;19(5):2763. doi:10.3390/ijerph19052763
Kaya GK, Ward J, Clarkson J. A review of risk matrices used in acute hospitals in England. Risk Anal. 2019;39(5):1060-1070. doi:10.1111/risa.13221
Lemmens SMP, Lopes van Balen VA, Röselaers YCM, Scheepers HCJ, Spaanderman MEA. The risk matrix approach: a helpful tool weighing probability and impact when deciding on preventive and diagnostic interventions. BMC Health Serv Res. 2022;22(1):218. doi:10.1186/s12913-022-07484-7
Taibi Y, Metzler YA, Bellingrath S, Neuhaus CA, Müller A. Applying risk matrices for assessing the risk of psychosocial hazards at work. Front Public Health. 2022;10:965262. doi:10.3389/fpubh.2022.965262
Vilaragut JJ, Duménigo C, Delgado JM, et al. Prevention of accidental exposure in radiotherapy: the risk matrix approach. Health Phys. 2013;104(2):139-150. doi:10.1097/HP.0b013e3182680379
Coles G, Fuller B, Nordquist K, Kongslie A. Using failure mode effects and criticality analysis for high-risk processes at three community hospitals. Jt Comm J Qual Patient Saf. 2005;31(3):132-140. doi:10.1016/S1553-7250(05)31018-X
Jen WY, Chan ZY, Lee YM, et al. Reducing chemotherapy waiting times in the ambulatory setting of a tertiary cancer centre using a design thinking approach. Cancer. 2023;15(18):4625. doi:10.3390/cancers15184625
Blackmer J, Amoline K, Amancher J, et al. Leveraging advanced preparation of oncology medications: decreasing turnaround-times in an outpatient infusion center. J Oncol Pharm Pract. 2021;27(6):1454-1460. doi:10.1177/1078155220960222
Soh TIP, Tan YS, Hairom Z, et al. Improving wait times for elective chemotherapy through pre-preparation: a quality-improvement project at the National University Cancer Institute of Singapore. J Oncol Pract. 2015;11(1):e89-e94. doi:10.1200/JOP.2014.000356
Nerich V, Limat S, Demarchi M, et al. Computerized physician order entry of injectable antineoplastic drugs: an epidemiologic study of prescribing medication errors. Int J Med Inform. 2010;79(10):699-706. doi:10.1016/j.ijmedinf.2010.07.003
Cox LA Jr. What's wrong with risk matrices? Risk Anal. 2008;28(2):497-512. doi:10.1111/j.1539-6924.2008.01030.x